Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth
An interview with:
Christopher Booth, MD, FRCPC
Medical Oncologist and Professor, Queen’s University, Kingston, Canada
Comments from:
Rebecca Dent MD MSc,
Senior Consultant Medical Oncologist, Deputy Chief Executive Officer, National Cancer Centre, Singapore
CHICAGO— For patients with stage III and high-risk stage II colon cancer, a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival in a study reported at the 2025 Annual Meeting of the American Society of Clinical Oncology. The long-term, large, randomized phase three Canadian Cancer Trials Group CO.21 CHALLENGE study found that post-treatment exercise was both achievable and effective and brought benefits rivalling those of new cancer medicines.
Study leader Christopher Booth MD FRCPC, a medical oncologist and professor at Queen’s University in Kingston, Canada, told the Audio Journal of Oncology’s Peter Goodwin about his group’s findings and conclusions.
Rebecca Dent MD MSc, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre, Singapore, added her comments.
AUDIO JOURNAL OF ONCOLOGY:
Interviews with Christopher Booth and Rebecca Dent
ASCO 2025 ABTRACT
Abstract LBA3510:
A randomized phase III trial of the impact of a structured exercise program on disease–free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE)
Tags
Related Episodes
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA